Plain-English translation of NCT06718179 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a stent is placed in your heart artery during an emergency procedure, doctors typically prescribe two blood-thinning medications—prasugrel and aspirin—for about a year. This trial is testing whether you can safely stop taking prasugrel after just one month while continuing aspirin, rather than taking both medications for the full 12 months. The goal is to reduce bleeding complications while keeping your stent working safely.
Long-term use of two blood-thinning medications together can increase the risk of serious bleeding. Researchers want to know if a shorter duration of this combination might protect you from bleeding complications without increasing the risk of blood clots forming in your stent.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one stopping prasugrel after one month while continuing aspirin, or one continuing both medications for the full 12 months. You will take your assigned medications at home as directed and return for follow-up visits to check how you are doing. The study will monitor you for any signs of bleeding, blood clots, or other heart problems over the 12-month period.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Denmark